Payment overview · 2025
General Payments
$1,051.83
37 reported records · 12 companies
Healthcare provider profile · identity verified
James K Ensor, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GERMANTOWN, TN · NPI 1205811247
Verified facts
What the public records show
CMS Open Payments records show James K Ensor, MD received $1,051.83 in general payments during 2025 across 37 reported records.
C2N Diagnostics, LLC accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Otezla, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Otezla by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $244.49 | 23.2% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $221.34 | 21.0% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $141.98 | 13.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $116.02 | 11.0% | 6 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $100.91 | 9.6% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.18 | 5.8% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $46.37 | 4.4% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $31.02 | 3.0% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $24.87 | 2.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.74 | 2.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.76 | 2.3% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $15.15 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,051.83 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $244.49 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $141.98 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $116.02 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $112.84 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $108.50 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $108.50 | 5 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $100.91 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $61.18 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $46.37 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $31.02 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.39 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $24.87 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $24.87 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| OTEZLA otezla |
2025 | Otezla | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 67 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 252 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 226 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 225 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 203 | 44 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 107 | 15 |
| Clonazepam | Clonazepam | 93 | 15 |
| Amlodipine Besylate | Amlodipine Besylate | 87 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 25 |
| Omeprazole | Omeprazole | 80 | 23 |
| Morphine Sulfate Er | Morphine Sulfate | 79 | suppressed |
| Lorazepam | Lorazepam | 78 | 13 |
| Mounjaro | Tirzepatide | 76 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 72 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 72 | 11 |
| Carisoprodol | Carisoprodol | 71 | 13 |
| Simvastatin | Simvastatin | 71 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 67 | 13 |
| Ozempic | Semaglutide | 67 | 15 |
| Pregabalin | Pregabalin | 65 | 22 |
| Atorvastatin Calcium | Atorvastatin Calcium | 64 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 13 |
| Atenolol | Atenolol | 59 | 15 |
| Fluconazole | Fluconazole | 59 | 19 |
| Lisinopril | Lisinopril | 59 | suppressed |
| Temazepam | Temazepam | 58 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 16 |
| Sertraline Hcl | Sertraline Hcl | 54 | 13 |
| Gabapentin | Gabapentin | 53 | 12 |
| Ezetimibe | Ezetimibe | 52 | 15 |
| Eliquis | Apixaban | 49 | suppressed |
| Entresto | Sacubitril/Valsartan | 49 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 29 |
| Metformin Hcl | Metformin Hcl | 45 | 14 |
| Alendronate Sodium | Alendronate Sodium | 44 | 14 |
| Donepezil Hcl | Donepezil Hcl | 44 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 12 |
| Bumetanide | Bumetanide | 40 | 15 |
| Montelukast Sodium | Montelukast Sodium | 40 | suppressed |
| Primidone | Primidone | 40 | suppressed |
| Azithromycin | Azithromycin | 38 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 38 | suppressed |
| Meloxicam | Meloxicam | 37 | 13 |
| Spironolactone | Spironolactone | 37 | suppressed |
| Topiramate | Topiramate | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 15 |
| Celecoxib | Celecoxib | 36 | suppressed |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 23 |
| Methylprednisolone | Methylprednisolone | 34 | 28 |
| Trazodone Hcl | Trazodone Hcl | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Fentanyl | Fentanyl | 32 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 32 | 11 |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Furosemide | Furosemide | 29 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 28 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 27 | 14 |
| Potassium Chloride | Potassium Chloride | 27 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 14 |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Prednisone | Prednisone | 24 | suppressed |
| Pentoxifylline | Pentoxifylline | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Carvedilol | Carvedilol | 21 | suppressed |
| Losartan Potassium | Losartan Potassium | 21 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Vytorin | Ezetimibe/Simvastatin | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Cimetidine | Cimetidine | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,051.83 · 37 records | C2N Diagnostics, LLC | AIRSUPRA, BREZTRI, CAPVAXIVE, DALVANCE, EVENITY, FFRct, Fluad, Flucelvax, Korlym, LEQVIO, OTEZLA, Ozempic, PRECIVITYAD2, REPATHA, Rybelsus, VERQUVO, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Otezla play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error